IP Library Granted Patent US 8,357,364
Granted Patent B2
US 8,357,364 · App. 12/882,554 · Granted Jan 22, 2013

Bone substitute compositions, methods of preparation and clinical applications

Inventors: Prashant Nagesh Kumta (Pittsburgh, PA); Charles S. Sfeir (Pittsburgh, PA); Abhijit Roy (Pittsburgh, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,357,364
App. No.
12/882,554
Granted
Jan 22, 2013
Kind
B2
Abstract

The present invention relates to bone substitute compositions and methods of their preparation, and their use in a wide variety of clinical applications. The compositions include calcium phosphate, acidic calcium salt, basic calcium salt, sodium hydrogen phosphate and porogen. The compositions further include a mixing liquid. The compositions can optionally include biological signaling molecules and/or a growth compound. Further, the compositions can optionally include a plasticizer.

Claims (52)

1. A bone substitute composition, comprising:

a powder component, comprising:

calcium phosphate;

acidic calcium salt;

basic calcium salt;

material selected from the group consisting of monosodium hydrogen phosphate, disodium hydrogen phosphate, and mixtures thereof; and

porogen; and

a liquid component, comprising:

a colloidal mixture comprising nanoparticulate calcium phosphate and calcium salt, the nanoparticulate calcium phosphate formed by reaction of calcium and non-acidic ionic phosphate in the presence of hydroxyl ions,

wherein calcium ions are present in excess in the reaction as compared to phosphate ions, and

wherein the composition is effective to regenerate bone in the absence of a biological growth component.

2. The composition of claim 1 , further comprising a plasticizer.

3. The composition of claim 2 , wherein the plasticizer is present in the powder component.

4. The composition of claim 1 , wherein the calcium phosphate is selected from the group consisting of monocalcium monophosphate anhydrite, calcium hydrogenphosphate dihydrate, calcium hydrogenphosphate anhydrite, hydroxyapatite, alpha-tricalcium phosphate, beta-tricalcium phosphate, fluorapatite, octacalcium phosphate, tetracalcium phosphate, carbonated calcium phosphate and mixtures thereof.

5. The composition of claim 1 , wherein the calcium phosphate comprises alpha-tricalcium phosphate.

6. The composition of claim 1 , wherein the acidic calcium salt is selected from the group consisting of calcium sulfate, calcium hydrogenphosphate dihydrate, calcium hydrogenphosphate anhydrite, calcium oxalate, calcium citrate, calcium tartrate, calcium picrate and mixtures thereof.

7. The composition of claim 1 , wherein the acidic calcium salt comprises calcium sulfate.

8. The composition of claim 1 , wherein the basic calcium salt is selected from the group consisting of calcium carbonate, calcium bicarbonate, calcium dihydroxide, and mixtures thereof.

9. The composition of claim 1 , wherein the basic calcium salt is calcium carbonate.

10. The composition of claim 1 , wherein the porogen is selected from the group consisting of recrystallized organic salt, recrystallized inorganic salt, engineered peptide, natural polymer, a composite of natural and synthetic polymers, synthetic biodegradable polymer, natural extra cellular matrix protein, and mixtures thereof.

11. The composition of claim 10 , wherein the natural polymer is selected from the group consisting of mannitol, collagen, sucrose, fibrin, gelatin, alginate, chitosan, fibrin-gelatin composite, paraffin, polyol, polylactic-co-glycolic acid, and mixtures thereof.

12. The composition of claim 10 , wherein the synthetic biodegradable polymer is selected from the group consisting of poly-lactic acid, poly-e-caprolactone, poly-lactic-co-glycolic acid, and mixtures thereof.

13. The composition of claim 10 , wherein the natural extra cellular matrix protein comprises urinary bladder matrix.

14. The composition of claim 1 , wherein the biological growth component comprises BMP-2.

15. The composition of claim 2 , wherein the plasticizer may be selected from the group consisting of sodium dextran sulfate, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alginic acid, sodium salt, polyvinyl pyrrolidone, hyaluronic acid, potassium salt, chondroitin sulfate, chitosan lactate, hydroxypropyl methylcellulose, carboxymethyl cellulose and mixtures thereof.

16. The composition of claim 1 , wherein the calcium phosphate is present in an amount of from about 50 to about 98 percent by weight based on the total weight of the composition.

17. The composition of claim 1 , wherein the porogen is present in an amount of from about 1 to about 60 percent by weight based on the total weight of the composition without the porogen.

18. The composition of claim 2 , wherein the composition is in a form capable of being injected into a patient.

19. The composition of claim 1 , wherein the colloidal mixture comprising nanoparticulate calcium phosphate is complexed with at least one of a compound selected from the group consisting of protein, peptide, DNA, drug, stem cell, normal cell, and combinations thereof.

20. The composition of claim 1 , having a porosity of about 80 percent or greater.

21. A bone substitute composition, comprising:

a powder component, comprising:

calcium phosphate;

acidic calcium salt;

basic calcium salt;

material selected from the group consisting of monosodium hydrogen phosphate, disodium hydrogen phosphate, and mixtures thereof; and

porogen; and

a liquid component, comprising:

a colloidal mixture comprising nanoparticulate calcium phosphate and calcium salt, the nanoparticulate calcium phosphate formed by reaction of calcium and non-acidic ionic phosphate in the presence of hydroxyl ions,

wherein calcium ions are present in excess in the reaction as compared to phosphate ions, and

wherein the porogen is present in an amount such that the composition has a porosity of about 80% or greater.

22. The composition of claim 21 , wherein the composition has a surface area of from about 60 m 2 /g to about 120 m 2 /g.

23. The composition of claim 21 , wherein the composition has a neutral pH.

24. The composition of claim 21 , wherein the composition further comprises a plasticizer.

25. The composition of claim 21 , wherein the composition is osteo-inductive.

26. The bone substitute composition of claim 1 , for use in clinical applications to repair or replace defective native bone tissue, comprising:

obtaining a patient having defective native bone tissue; and

administering in vivo the bone substitute composition of claim 1 in a form selected from the group consisting of paste, putty and cement, into the patient at the site of the defective native bone tissue.

27. The bone substitute composition of claim 26 , wherein the native bone tissue is in an area selected from the group consisting of orthopedic, dental and craniofacial.

28. The bone substitute composition of claim 1 , wherein the hydroxyl ions comprise hydroxide material selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, tetraalkyl ammonium hydroxide, and mixtures thereof.

29. The bone substitute composition of claim 1 , wherein the non-acidic ionic phosphate is selected from the group consisting of trisodium phosphate, tripotassium phosphate, tris(tetra-alkyl)ammonium phosphate.

30. The bone substitute composition of claim 1 , wherein the reaction of calcium and non-acidic ionic phosphate further includes the presence of a buffer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2011
From: KUMTA, PRASHANT N.; SFEIR, CHARLES S.; ROY, ABHIJIT
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 027378/0466 →
CONFIRMATORY LICENSE Recorded Dec 9, 2010
From: UNIVERSITY OF PITTSBURGH
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 025457/0665 →
Continuity (2)
Provisional Application 61242596 · Sep 15, 2009
Related Publication 20110064703A1 · Mar 17, 2011